These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 16319686)

  • 1. Leukocyte adhesion and the pathophysiology of sickle cell disease.
    Okpala I
    Curr Opin Hematol; 2006 Jan; 13(1):40-4. PubMed ID: 16319686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice.
    Almeida CB; Scheiermann C; Jang JE; Prophete C; Costa FF; Conran N; Frenette PS
    Blood; 2012 Oct; 120(14):2879-88. PubMed ID: 22833547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sickle red cell-endothelium interactions.
    Kaul DK; Finnegan E; Barabino GA
    Microcirculation; 2009 Jan; 16(1):97-111. PubMed ID: 18720225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dietary ω-3 fatty acids protect against vasculopathy in a transgenic mouse model of sickle cell disease.
    Kalish BT; Matte A; Andolfo I; Iolascon A; Weinberg O; Ghigo A; Cimino J; Siciliano A; Hirsch E; Federti E; Puder M; Brugnara C; De Franceschi L
    Haematologica; 2015 Jul; 100(7):870-80. PubMed ID: 25934765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The fucosylation inhibitor, 2-fluorofucose, inhibits vaso-occlusion, leukocyte-endothelium interactions and NF-ĸB activation in transgenic sickle mice.
    Belcher JD; Chen C; Nguyen J; Abdulla F; Nguyen P; Nguyen M; Okeley NM; Benjamin DR; Senter PD; Vercellotti GM
    PLoS One; 2015; 10(2):e0117772. PubMed ID: 25706118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion.
    Belcher JD; Marker PH; Weber JP; Hebbel RP; Vercellotti GM
    Blood; 2000 Oct; 96(7):2451-9. PubMed ID: 11001897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Participation of Mac-1, LFA-1 and VLA-4 integrins in the in vitro adhesion of sickle cell disease neutrophils to endothelial layers, and reversal of adhesion by simvastatin.
    Canalli AA; Proença RF; Franco-Penteado CF; Traina F; Sakamoto TM; Saad ST; Conran N; Costa FF
    Haematologica; 2011 Apr; 96(4):526-33. PubMed ID: 21173096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omega 3 (n-3) fatty acids down-regulate nuclear factor-kappa B (NF-κB) gene and blood cell adhesion molecule expression in patients with homozygous sickle cell disease.
    Daak AA; Elderdery AY; Elbashir LM; Mariniello K; Mills J; Scarlett G; Elbashir MI; Ghebremeskel K
    Blood Cells Mol Dis; 2015 Jun; 55(1):48-55. PubMed ID: 25976467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydroxycarbamide reduces eosinophil adhesion and degranulation in sickle cell anaemia patients.
    Pallis FR; Conran N; Fertrin KY; Olalla Saad ST; Costa FF; Franco-Penteado CF
    Br J Haematol; 2014 Jan; 164(2):286-95. PubMed ID: 24383847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydroxycarbamide decreases sickle reticulocyte adhesion to resting endothelium by inhibiting endothelial lutheran/basal cell adhesion molecule (Lu/BCAM) through phosphodiesterase 4A activation.
    Chaar V; Laurance S; Lapoumeroulie C; Cochet S; De Grandis M; Colin Y; Elion J; Le Van Kim C; El Nemer W
    J Biol Chem; 2014 Apr; 289(16):11512-11521. PubMed ID: 24616094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of hydroxyurea on the membrane of erythrocytes and platelets in sickle cell anemia.
    Covas DT; de Lucena Angulo I; Vianna Bonini Palma P; Zago MA
    Haematologica; 2004 Mar; 89(3):273-80. PubMed ID: 15020264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of Sickle Red Blood Cell Adhesion and its Associated Changes in Biomarkers by Sulfated Nonanticoagulant Heparin Derivative.
    Alshaiban A; Muralidharan-Chari V; Nepo A; Mousa SA
    Clin Appl Thromb Hemost; 2016 Apr; 22(3):230-8. PubMed ID: 25601897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea.
    Styles LA; Lubin B; Vichinsky E; Lawrence S; Hua M; Test S; Kuypers F
    Blood; 1997 Apr; 89(7):2554-9. PubMed ID: 9116302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of vascular endothelial cell adhesion molecule expression by sickle blood cells.
    Brown MD; Wick TM; Eckman JR
    Pediatr Pathol Mol Med; 2001; 20(1):47-72. PubMed ID: 12673844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epinephrine-induced activation of LW-mediated sickle cell adhesion and vaso-occlusion in vivo.
    Zennadi R; Moeller BJ; Whalen EJ; Batchvarova M; Xu K; Shan S; Delahunty M; Dewhirst MW; Telen MJ
    Blood; 2007 Oct; 110(7):2708-17. PubMed ID: 17609430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between the clinical manifestations of sickle cell disease and the expression of adhesion molecules on white blood cells.
    Okpala I; Daniel Y; Haynes R; Odoemene D; Goldman J
    Eur J Haematol; 2002 Sep; 69(3):135-44. PubMed ID: 12406006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levels of endothelial, neutrophil and platelet-specific factors in sickle cell anemia patients during hydroxyurea therapy.
    Saleh AW; Hillen HF; Duits AJ
    Acta Haematol; 1999; 102(1):31-7. PubMed ID: 10473885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RNA aptamer therapy for vaso-occlusion in sickle cell disease.
    Burnette AD; Nimjee SM; Batchvarova M; Zennadi R; Telen MJ; Nishimura J; Sullenger BA
    Nucleic Acid Ther; 2011 Aug; 21(4):275-83. PubMed ID: 21793788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease.
    Belcher JD; Chen C; Nguyen J; Milbauer L; Abdulla F; Alayash AI; Smith A; Nath KA; Hebbel RP; Vercellotti GM
    Blood; 2014 Jan; 123(3):377-90. PubMed ID: 24277079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
    Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.